PURPOSE: The aim of this study was to assess the clinical outcome of redifferentiation therapy using retinoic acid (RA) in combination with 131I therapy, and to identify biological parameters that predict therapeutic response in Korean patients with radioiodine-refractory papillary thyroid carcinoma (PTC). MATERIALS AND METHODS: A total of 47 patients (13 men, 34 women; age 54.2±13.6 years) with radioiodine-refractory PTC underwent therapy consisting of consecutive treatment with 131I and RA. Each 131I/RA treatment cycle involved the administration of oral isotretinoin for 6 weeks at 1-1.5 mg/kg daily followed by a single oral dose of 131I (range 5.5-16.7 GBq). Therapeutic responses were determined using serum thyroglobulin (Tg) levels and the change in tumour size 6 months after completing the 131I/RA therapy. Biological parameters and pathological parameters before and after combined therapy were compared. RESULTS: After completing 131I/RA therapy, 1 patient showed a complete response, 9 partial response, 9 stable disease, and 28 progressive disease, representing an overall response rate of 21.3%. Univariate analysis revealed that an age of <45 years and a persistently high serum Tg level were related to a good response. No clinical response was achieved when metastases showing no iodine uptake were present. Multivariate regression analysis showed that an age of <45 years was significantly associated with a good response. Of the 24 patients with well-differentiated carcinoma, 5 (20.8%) responded to 131I/RA therapy, whereas all 6 patients with poorly differentiated carcinoma failed to respond. CONCLUSION: 131I/RA therapy was found to elicit a response rate of 21.3% among patients with radioiodine-refractory PTC, and an age of <45 years was found to be significantly associated with a good response.
PURPOSE: The aim of this study was to assess the clinical outcome of redifferentiation therapy using retinoic acid (RA) in combination with 131I therapy, and to identify biological parameters that predict therapeutic response in Korean patients with radioiodine-refractory papillary thyroid carcinoma (PTC). MATERIALS AND METHODS: A total of 47 patients (13 men, 34 women; age 54.2±13.6 years) with radioiodine-refractory PTC underwent therapy consisting of consecutive treatment with 131I and RA. Each 131I/RA treatment cycle involved the administration of oral isotretinoin for 6 weeks at 1-1.5 mg/kg daily followed by a single oral dose of 131I (range 5.5-16.7 GBq). Therapeutic responses were determined using serum thyroglobulin (Tg) levels and the change in tumour size 6 months after completing the 131I/RA therapy. Biological parameters and pathological parameters before and after combined therapy were compared. RESULTS: After completing 131I/RA therapy, 1 patient showed a complete response, 9 partial response, 9 stable disease, and 28 progressive disease, representing an overall response rate of 21.3%. Univariate analysis revealed that an age of <45 years and a persistently high serum Tg level were related to a good response. No clinical response was achieved when metastases showing no iodine uptake were present. Multivariate regression analysis showed that an age of <45 years was significantly associated with a good response. Of the 24 patients with well-differentiated carcinoma, 5 (20.8%) responded to 131I/RA therapy, whereas all 6 patients with poorly differentiated carcinoma failed to respond. CONCLUSION:131I/RA therapy was found to elicit a response rate of 21.3% among patients with radioiodine-refractory PTC, and an age of <45 years was found to be significantly associated with a good response.
Authors: D Simon; C Körber; M Krausch; J Segering; P Groth; R Görges; F Grünwald; H W Müller-Gärtner; C Schmutzler; J Köhrle; H D Röher; C Reiners Journal: Eur J Nucl Med Mol Imaging Date: 2002-03-13 Impact factor: 9.236
Authors: P E Goretzki; D Simon; A Frilling; J Witte; C Reiners; M Grussendorf; F A Horster; H D Röher Journal: Br J Surg Date: 1993-08 Impact factor: 6.939
Authors: C A Fernández; M Puig-Domingo; F Lomeña; M Estorch; V Camacho Martí; A L Bittini; M Marazuela; J Santamaría; J Castro; P Martínez de Icaya; I Moraga; T Martín; A Megía; M Porta; D Mauricio; I Halperin Journal: J Endocrinol Invest Date: 2009-03 Impact factor: 4.256
Authors: Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Lara Lima-Antoine; Julianna Lys de Sousa Alves Neri; Thaisa Cristina Tavares de Melo; Isabela Samária Fernandes Leite; Diego Marques da Costa Santos; Jéssica Nayara Góes de Araújo; Ana Gabriella da Costa Lemos Silva; Nathália Kelly de Araújo; Carlos C de Oliveira Ramos; Sheila Ramos de Miranda Henriques Tarrapp; Andre Ducati Luchessi; Clélia de Oliveira Lyra; Karla Danielly da Silva Ribeiro; Vivian Nogueira Silbiger Journal: Eur J Clin Nutr Date: 2021-07-06 Impact factor: 4.016